acetaminophen has been researched along with Chronic Pain in 92 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Chronic Pain: Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.
Excerpt | Relevance | Reference |
---|---|---|
"Hydrocodone/acetaminophen combination analgesics are frequently prescribed for chronic pain management; however, acetaminophen presents potential hepatotoxicity to patients and thus dose limitations." | 9.20 | Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain. ( Bartoli, A; He, E; Michna, E; Wen, W, 2015) |
"The goal of this study was to evaluate the efficacy and safety of extended-release tramadol hydrochloride 75-mg/acetaminophen 650-mg fixed-dose combination tablets (TA-ER) for the treatment of chronic low back pain." | 9.17 | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain. ( Lee, CS; Lee, JH, 2013) |
"The aim of the present study was to investigate the effect of perioperative administration of pregabalin on postoperative acute and chronic pain and analgesic requirements." | 9.16 | Perioperative pregabalin for acute and chronic pain after abdominal hysterectomy or myomectomy: a randomised controlled trial. ( Fassoulaki, A; Melemeni, A; Paraskeva, A; Tsaroucha, A, 2012) |
"Ibuprofen and paracetamol have long been used as analgesics in a range of acute, intermittent and chronic pain conditions." | 8.91 | Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. ( Aldington, DJ; Derry, S; Moore, RA; Straube, S; Wiffen, PJ, 2015) |
" The patient was weaned from oxycodone ER 30 mg every 12 h and oxycodone/acetaminophen 10/325 mg 3x/day for breakthrough pain utilizing an unconventional approach." | 8.31 | Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report. ( Patel, KV; Sahni, S; Taylor, LF, 2023) |
"Pregabalin in the context of multimodal pain management may be associated with reduced opioid consumption and other medical complications in patients undergoing TKA, including previous users of chronic pain medications." | 7.80 | Pregabalin reduces opioid consumption and improves outcome in chronic pain patients undergoing total knee arthroplasty. ( Chen, AF; Hozack, WJ; Parvizi, J; Sawan, H; Viscusi, ER, 2014) |
"A total of 400 elderly patients with osteoarthritis of the hip and knee will be recruited from five institutions in Japan." | 7.30 | Protocol for the RETHINK study: a randomised, double-blind, parallel-group, non-inferiority clinical trial comparing acetaminophen and NSAIDs for treatment of chronic pain in elderly patients with osteoarthritis of the hip and knee. ( Aono, H; Endo, M; Hara, T; Kawahara, S; Kawano, T; Mawatari, T; Miyaji, T; Miyake, M; Nakashima, Y; Sakamoto, S; Sato, T; Shimokawa, M; Takano, T; Tokunaga, M; Zenda, S, 2023) |
" IR/ER HB/APAP tablets deliver 25% of the HB dose and 50% of the APAP dose by IR and the remainder by ER over a 12-hour dosing interval." | 6.80 | Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain. ( Barrett, T; Chen, Y; Giuliani, MJ; Hisaw, E; Kostenbader, K; Young, JL; Zheng, Y, 2015) |
" After cross-reference searches of both trials and 38 reviews, seven studies comparing acetaminophen in continuous dosing regimens of more than 2 weeks with placebo were included." | 6.53 | Acetaminophen for Chronic Pain: A Systematic Review on Efficacy. ( Dideriksen, D; Ennis, ZN; Handberg, G; Pottegård, A; Vaegter, HB, 2016) |
"Acetaminophen's role in chronic pain conditions is understudied." | 5.56 | Attitudes toward and Barriers to Acetaminophen Use in the Chronic Pain Population: A Cross-Sectional Study. ( Foo, RMC; Hoff, C; Sekhri, NK; Weber, G, 2020) |
"Tramadol-acetaminophen was effective at reducing chronic LBP and conferred a prophylactic motivational effect in patients with chronic LBP." | 5.43 | Effect of Tramadol/Acetaminophen on Motivation in Patients with Chronic Low Back Pain. ( Nishida, K; Ozaki, T; Takei, Y; Tanaka, M; Tetsunaga, T, 2016) |
"Acetaminophen exposure was a time-dependent variable." | 5.42 | Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort. ( Dawson, J; Dominiczak, AF; Fulton, RL; McInnes, GT; Meredith, PA; Morrison, DS; Morton, R; Padmanabhan, S; Touyz, RM; Walters, MR, 2015) |
"Analgesic treatment did not reduce depression while placebo appeared to improve depressive symptoms significantly by comparison, possibly owing to the adverse effects of active buprenorphine." | 5.27 | Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). ( Aarsland, D; Ballard, C; Erdal, A; Flo, E; Husebo, BS; Slettebo, DD, 2018) |
"Anesthesia, acetaminophen, Persistent surgical pain, Postoperative acute pain." | 5.27 | Acetaminophen reduces acute and persistent incisional pain after hysterectomy. ( Akkurt, C; Hakimoglu, S; Koyuncu, O; Sessler, D; Turan, A; Turhanoglu, S; Ugur, M, 2018) |
"Hydrocodone/acetaminophen combination analgesics are frequently prescribed for chronic pain management; however, acetaminophen presents potential hepatotoxicity to patients and thus dose limitations." | 5.20 | Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain. ( Bartoli, A; He, E; Michna, E; Wen, W, 2015) |
"The goal of this study was to evaluate the efficacy and safety of extended-release tramadol hydrochloride 75-mg/acetaminophen 650-mg fixed-dose combination tablets (TA-ER) for the treatment of chronic low back pain." | 5.17 | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain. ( Lee, CS; Lee, JH, 2013) |
"The aim of the present study was to investigate the effect of perioperative administration of pregabalin on postoperative acute and chronic pain and analgesic requirements." | 5.16 | Perioperative pregabalin for acute and chronic pain after abdominal hysterectomy or myomectomy: a randomised controlled trial. ( Fassoulaki, A; Melemeni, A; Paraskeva, A; Tsaroucha, A, 2012) |
" Paracetamol (acetaminophen; APAP) is the first intention treatment of chronic pain that is highly prevalent and persistent in the elderly." | 4.98 | Impact of medication on protein and amino acid metabolism in the elderly: the sulfur amino acid and paracetamol case. ( Dardevet, D; Mast, C; Papet, I, 2018) |
"Paracetamol (acetaminophen) is the most commonly used drug in the world, with a long record of use in acute and chronic pain." | 4.98 | Long-term adverse effects of paracetamol - a review. ( Dear, JW; MacIntyre, IM; McCrae, JC; Morrison, EE; Webb, DJ, 2018) |
" New evidence found that acetaminophen was ineffective for acute low back pain, nonsteroidal anti-inflammatory drugs had smaller benefits for chronic low back pain than previously observed, duloxetine was effective for chronic low back pain, and benzodiazepines were ineffective for radiculopathy." | 4.95 | Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. ( Chou, R; Dana, T; Deyo, R; Friedly, J; Fu, R; Griffin, J; Grusing, S; Kraegel, P; Skelly, A; Weimer, M, 2017) |
"Ibuprofen and paracetamol have long been used as analgesics in a range of acute, intermittent and chronic pain conditions." | 4.91 | Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions. ( Aldington, DJ; Derry, S; Moore, RA; Straube, S; Wiffen, PJ, 2015) |
" The patient was weaned from oxycodone ER 30 mg every 12 h and oxycodone/acetaminophen 10/325 mg 3x/day for breakthrough pain utilizing an unconventional approach." | 4.31 | Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report. ( Patel, KV; Sahni, S; Taylor, LF, 2023) |
"Regression analysis showed that severe spinal cord injury and peri-treatment use of acetaminophen dihydrocodeine were both one of the risk factors for postoperative chronic pain." | 4.02 | A retrospective analysis of the effects of different analgesics on the pain of patients with traumatic thoracolumbar fractures in the peri-treatment period. ( Chang, QY; Chen, J; Gan, ZJ; Li, TT; Wang, YT; Wen, S; Xiong, LL; Yuan, H, 2021) |
"Paracetamol (acetaminophen) is widely used for management of mild-to-moderate pain and reduction of fever." | 3.91 | Efficacy and safety of modified-release paracetamol for acute and chronic pain: a systematic review protocol. ( Dosenovic, S; Margan Koletic, Z; Puljak, L, 2019) |
" In 1980 s, the relevance of aspirin for Reye's syndrome became a problem, then acetaminophen came into use for various kinds of cases such as children, pregnant women and the elderly for pain management or alleviation of fever." | 3.83 | [Side Effects of Acetaminophen and their Management]. ( Saeki, S, 2016) |
"This study is aimed at examining the long-term effects of chronic pain during early life (postnatal day 0 to 8weeks), and intervention using sucrose, on cognitive functions during adulthood in rats." | 3.81 | Sucrose-induced analgesia during early life modulates adulthood learning and memory formation. ( Alabwaini, J; Alzoubi, KH; Kassab, MI; Khabour, OF; Nuseir, KQ, 2015) |
"Pregabalin in the context of multimodal pain management may be associated with reduced opioid consumption and other medical complications in patients undergoing TKA, including previous users of chronic pain medications." | 3.80 | Pregabalin reduces opioid consumption and improves outcome in chronic pain patients undergoing total knee arthroplasty. ( Chen, AF; Hozack, WJ; Parvizi, J; Sawan, H; Viscusi, ER, 2014) |
"A total of 400 elderly patients with osteoarthritis of the hip and knee will be recruited from five institutions in Japan." | 3.30 | Protocol for the RETHINK study: a randomised, double-blind, parallel-group, non-inferiority clinical trial comparing acetaminophen and NSAIDs for treatment of chronic pain in elderly patients with osteoarthritis of the hip and knee. ( Aono, H; Endo, M; Hara, T; Kawahara, S; Kawano, T; Mawatari, T; Miyaji, T; Miyake, M; Nakashima, Y; Sakamoto, S; Sato, T; Shimokawa, M; Takano, T; Tokunaga, M; Zenda, S, 2023) |
"The study included 113 breast cancer patients after breast cancer surgery with axillary lymphadenectomy treated with either 75/650 mg or 37." | 3.30 | Association of ( Besic, N; Dolzan, V; Goricar, K; Strazisar, B; Vidic, Z, 2023) |
"These exploratory results suggest that participation in N-of-1 trials may reduce long-term use of NSAIDs; there is also a weak signal for an effect on use of opioids." | 2.94 | Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial. ( Cabrera, R; Duan, N; Henry, SG; Kravitz, RL; Marois, MT; Odineal, DD; Schmid, CH; Sim, I; Wang, Y; Ward, D; Wilsey, B, 2020) |
"Chronic pain is associated with impaired regulation of cardiovascular and analgesia systems, which may predispose to persistent BP elevation." | 2.82 | The Effects of Pain and Analgesic Medications on Blood Pressure. ( Coscarelli, A; Giordano, A; Menale, S; Rivasi, G; Turrin, G; Ungar, A, 2022) |
" IR/ER HB/APAP tablets deliver 25% of the HB dose and 50% of the APAP dose by IR and the remainder by ER over a 12-hour dosing interval." | 2.80 | Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain. ( Barrett, T; Chen, Y; Giuliani, MJ; Hisaw, E; Kostenbader, K; Young, JL; Zheng, Y, 2015) |
"It is essential to find good postoperative pain control strategies that facilitate early mobility, early recovery, and early hospital discharge with minimal side effects on the mother and infant." | 2.66 | Strategies of analgesic treatment after cesarean delivery. Current state and new alternatives. ( Arroyo-Fernández, FJ; Calderón Seoane, JE; Torres Morera, LM, 2020) |
" However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications." | 2.66 | Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. ( Guevara, N; Guido, PC; Maldonado, C; Schaiquevich, P; Vázquez, M, 2020) |
"Acetaminophen has been commonly used as the fi rst-line treatment for OA pain and cLBP, but its long-term use is not recommended based on recent evidence." | 2.61 | Evidence-Based Recommendations on the Pharmacological Management of Osteoarthritis and Chronic Low Back Pain: An Asian Consensus ( Ip, AKK; Murakami, T; Shin, HK; Sun, WZ; Tam, CK; Ushida, T; Wang, JH; Williamson, OD; Yabuki, S, 2019) |
"Chronic pain is a main symptom of many diseases in internal medicine." | 2.58 | [Errors and Solutions During Medical Therapy for Chronic Pain]. ( Häuser, W; Schuler, M, 2018) |
" The recommended dosage in the UK, Europe, Australia, and the USA for children and adolescents is generally 10 to 15 mg/kg every four to six hours, with specific age ranges from 60 mg (6 to 12 months old) up to 500 to 1000 mg (over 12 years old)." | 2.55 | Paracetamol (acetaminophen) for chronic non-cancer pain in children and adolescents. ( Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM; Williams, DG, 2017) |
" After cross-reference searches of both trials and 38 reviews, seven studies comparing acetaminophen in continuous dosing regimens of more than 2 weeks with placebo were included." | 2.53 | Acetaminophen for Chronic Pain: A Systematic Review on Efficacy. ( Dideriksen, D; Ennis, ZN; Handberg, G; Pottegård, A; Vaegter, HB, 2016) |
"For a woman with chronic pain, adequate use of pain killers during pregnancy is needed." | 2.53 | Ongoing Pharmacological Management of Chronic Pain in Pregnancy. ( Källén, B; Reis, M, 2016) |
"Quality pain management for cancer survivors is complicated by the fact that cancer-related pain can be due to the tumor, surgery, radiation, and/or chemotherapy." | 2.50 | Understanding the cancer pain experience. ( Schreiber, JA, 2014) |
"Appropriate treatment of pain requires an understanding of the characteristics of pain, including the severity and the nature of the pain-for example, acute versus chronic pain or nociceptive versus neuropathic pain." | 2.49 | An overview of pain management: the clinical efficacy and value of treatment. ( Nalamachu, S, 2013) |
"Chronic pain is a debilitating condition that is associated with many common diseases; this places a major burden on the healthcare system." | 2.48 | Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. ( Cherubino, P; Fornasari, D; Labianca, R; Sarzi-Puttini, P; Vellucci, R; Zuccaro, SM, 2012) |
"Postoperative chronic pain in spine surgery can be caused by damage or instability of spinal column; pressure on nerves or segment of spinal cord; or can be due to long lasting nociception caused by inflammation, infection or tumour." | 2.48 | [Chronic pain following spine surgery]. ( Derbent, A; Uyar, M; Yilmaz, B, 2012) |
"In case of neuropathic pain, the benefit deriving from the use of a single active principle is relative." | 2.48 | [Skin ulcer pain]. ( Guerra, L; Pellicano, R, 2012) |
"More than 1 billion people live with chronic pain, including 100 million Americans, with a majority utilizing prescription and over-the-counter (OTC) pain medications." | 1.91 | Perceptions of West Virginia Teens and Adults Regarding the Risks of Over-the-Counter Pain Medications. ( Garofoli, M; Hanif, A; Kuhn, S; Sraj, S, 2023) |
"To investigate if chronic pain in children with cerebral palsy is undertreated with the current pharmacological/non-pharmacological interventions using a pain management index." | 1.91 | Presence and grade of undertreatment of pain in children with cerebral palsy. ( Sultan, T; Wong, C, 2023) |
"Osteoarthritis (OA) is a chronic painful condition that often affects large joints such as the knee." | 1.91 | Analgesic utilization in people with knee osteoarthritis: A population-based study using primary care data. ( Gran, S; Knaggs, RD; Taqi, A, 2023) |
"Most migraine guidelines now recommend paracetamol for mild to moderate pain." | 1.72 | Practice guidelines for the treatment of acute migraine and chronic knee osteoarthritis with paracetamol: an expert appraisal on evolution over time between scientific societies. ( Attal, N; Desmeules, J; Eschalier, A; Lanteri-Minet, M; Perrot, S, 2022) |
" At the time of intervention, her opioid dosage was between 50-90 MME (Morphine milligram equivalent) (Norco 8 × 7." | 1.56 | Physician-Delivered Pain Neuroscience Education for Opioid Tapering: A Case Report. ( Agarwal, V; Louw, A; Puentedura, EJ, 2020) |
"Acetaminophen's role in chronic pain conditions is understudied." | 1.56 | Attitudes toward and Barriers to Acetaminophen Use in the Chronic Pain Population: A Cross-Sectional Study. ( Foo, RMC; Hoff, C; Sekhri, NK; Weber, G, 2020) |
"Acute pain was associated with a variety of surgical procedures and patients were examined before and after surgical procedures." | 1.48 | The glycation products before and after therapy for acute and chronic pain. ( Fricová, J; Holeček, V; Houdek, K; Lejčko, J; Nedvídek, J; Rokyta, R; Trefil, L, 2018) |
"GR consumption improved mechanical and thermal allodynia and mechanical hyperalgesia and improved behavioural changes related to cognitive disturbances, anxiety, and depression." | 1.48 | Ginger rhizome enhances the anti-inflammatory and anti-nociceptive effects of paracetamol in an experimental mouse model of fibromyalgia. ( De la Puerta, R; Fernandez-Arche, A; Garcia-Gimenez, MD; Montserrat-de la Paz, S; Quilez, AM, 2018) |
" Suggested dosing regimens are proposed." | 1.46 | Oral Multimodal Analgesia for Total Joint Arthroplasty. ( Balch, KR; Dalury, DF; Golladay, GJ; Jiranek, WA; Satpathy, J, 2017) |
"We studied 599 participants who reported chronic pain at baseline." | 1.46 | Pain severity and pharmacologic pain management among community-living older adults: the MOBILIZE Boston study. ( Bean, JF; Leveille, SG; Nawai, A; Shmerling, RH; van der Leeuw, G, 2017) |
"However, elderly people with chronic pain rarely used the medications specifically for neuropathic pain." | 1.43 | Chronic pain among community-dwelling elderly: a population-based clinical study. ( Haanpää, M; Liira, H; Rapo-Pylkkö, S, 2016) |
"Tramadol-acetaminophen was effective at reducing chronic LBP and conferred a prophylactic motivational effect in patients with chronic LBP." | 1.43 | Effect of Tramadol/Acetaminophen on Motivation in Patients with Chronic Low Back Pain. ( Nishida, K; Ozaki, T; Takei, Y; Tanaka, M; Tetsunaga, T, 2016) |
" Collected data included socio-demographics, treatment information, incidence of adverse drug reactions (ADRs), numerical rating scale for intensity of pain, EuroQol-5D (EQ-5D) scale, and physician's global impression (PGI) during the 12 week observation period." | 1.42 | Overall safety profile and effectiveness of tramadol hydrochloride/acetaminophen in patients with chronic noncancer pain in Japanese real-world practice. ( Fujie, M; Kawai, K; Ogawa, Y; Suzuki, J; Yajima, T; Yokomori, J; Yoshizawa, K, 2015) |
"Acetaminophen exposure was a time-dependent variable." | 1.42 | Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort. ( Dawson, J; Dominiczak, AF; Fulton, RL; McInnes, GT; Meredith, PA; Morrison, DS; Morton, R; Padmanabhan, S; Touyz, RM; Walters, MR, 2015) |
"Among subjects reporting chronic pain the prevalence of OTC analgesic use was almost twice as high as among subjects without chronic pain." | 1.42 | Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription of opioids. ( Borchgrevink, PC; Dale, O; Fredheim, OM; Mahic, M; Romundstad, P; Skurtveit, S, 2015) |
"The target population was HIV and AIDS patients who had been using the primary health clinic for chronic pain management." | 1.39 | The management of HIV- and AIDS-related pain in a primary health clinic in Tshwane, South Africa. ( Dreyer Wright, SC; Makua, MR; Maree, JE, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 73 (79.35) | 24.3611 |
2020's | 19 (20.65) | 2.80 |
Authors | Studies |
---|---|
Perrot, S | 1 |
Eschalier, A | 1 |
Desmeules, J | 1 |
Lanteri-Minet, M | 1 |
Attal, N | 1 |
Rivasi, G | 1 |
Menale, S | 1 |
Turrin, G | 1 |
Coscarelli, A | 1 |
Giordano, A | 1 |
Ungar, A | 1 |
Patel, KV | 1 |
Sahni, S | 1 |
Taylor, LF | 1 |
Endo, M | 1 |
Kawahara, S | 1 |
Sato, T | 1 |
Tokunaga, M | 1 |
Hara, T | 1 |
Mawatari, T | 1 |
Kawano, T | 1 |
Zenda, S | 1 |
Miyaji, T | 1 |
Shimokawa, M | 1 |
Sakamoto, S | 1 |
Takano, T | 1 |
Miyake, M | 1 |
Aono, H | 1 |
Nakashima, Y | 1 |
Taqi, A | 1 |
Gran, S | 1 |
Knaggs, RD | 1 |
Garofoli, M | 1 |
Hanif, A | 1 |
Sraj, S | 1 |
Kuhn, S | 1 |
Vidic, Z | 1 |
Goricar, K | 1 |
Strazisar, B | 1 |
Besic, N | 1 |
Dolzan, V | 1 |
Sultan, T | 1 |
Wong, C | 1 |
Jin, L | 1 |
Liang, Y | 1 |
Yu, Y | 1 |
Miao, P | 1 |
Huang, Y | 1 |
Xu, L | 1 |
Wang, H | 1 |
Wang, C | 1 |
Huang, J | 1 |
Guo, K | 1 |
Odineal, DD | 1 |
Marois, MT | 1 |
Ward, D | 1 |
Schmid, CH | 1 |
Cabrera, R | 1 |
Sim, I | 1 |
Wang, Y | 1 |
Wilsey, B | 1 |
Duan, N | 1 |
Henry, SG | 1 |
Kravitz, RL | 1 |
Stevens, J | 1 |
Bhalla, T | 1 |
Margan Koletic, Z | 1 |
Dosenovic, S | 1 |
Puljak, L | 2 |
Arroyo-Fernández, FJ | 1 |
Calderón Seoane, JE | 1 |
Torres Morera, LM | 1 |
Foo, RMC | 1 |
Hoff, C | 1 |
Sekhri, NK | 1 |
Weber, G | 1 |
Dhokia, M | 1 |
Elander, J | 1 |
Clements, K | 1 |
Gilbert, P | 1 |
Agarwal, V | 1 |
Louw, A | 1 |
Puentedura, EJ | 1 |
Ide, K | 1 |
Fujiwara, T | 1 |
Shimada, N | 1 |
Tokumasu, H | 1 |
Vázquez, M | 1 |
Guevara, N | 1 |
Maldonado, C | 1 |
Guido, PC | 1 |
Schaiquevich, P | 1 |
Koes, B | 1 |
Schreijenberg, M | 1 |
Tkachev, A | 1 |
Migliorini, F | 1 |
Maffulli, N | 1 |
Eschweiler, J | 1 |
Betsch, M | 1 |
Catalano, G | 1 |
Driessen, A | 1 |
Tingart, M | 1 |
Baroncini, A | 1 |
Yuan, H | 1 |
Chang, QY | 1 |
Chen, J | 1 |
Wang, YT | 1 |
Gan, ZJ | 1 |
Wen, S | 1 |
Li, TT | 1 |
Xiong, LL | 1 |
Golladay, GJ | 1 |
Balch, KR | 1 |
Dalury, DF | 1 |
Satpathy, J | 1 |
Jiranek, WA | 1 |
Cooper, TE | 1 |
Fisher, E | 1 |
Anderson, B | 1 |
Wilkinson, NM | 1 |
Williams, DG | 1 |
Eccleston, C | 1 |
Montserrat-de la Paz, S | 1 |
Garcia-Gimenez, MD | 1 |
Quilez, AM | 1 |
De la Puerta, R | 1 |
Fernandez-Arche, A | 1 |
Visconti, A | 1 |
Krebs, EE | 1 |
Gravely, A | 1 |
Nugent, S | 1 |
Jensen, AC | 1 |
DeRonne, B | 1 |
Goldsmith, ES | 1 |
Kroenke, K | 1 |
Bair, MJ | 1 |
Noorbaloochi, S | 1 |
Mast, C | 1 |
Dardevet, D | 1 |
Papet, I | 1 |
Benitez-Camps, M | 1 |
Morros Padrós, R | 1 |
Pera-Pujadas, H | 1 |
Dalfó Baqué, A | 1 |
Bayó Llibre, J | 1 |
Rebagliato Nadal, O | 1 |
Cortès Martinez, J | 1 |
García Sangenís, A | 1 |
Roca Saumell, C | 1 |
Coll de Tuero, G | 1 |
Vinyoles-Bargalló, E | 1 |
Kaye, AD | 1 |
Cornett, EM | 1 |
Hart, B | 1 |
Patil, S | 1 |
Pham, A | 1 |
Spalitta, M | 1 |
Mancuso, KF | 1 |
Vellucci, R | 2 |
Terenzi, R | 1 |
Kanis, JA | 1 |
Kress, HG | 1 |
Mediati, RD | 1 |
Reginster, JY | 1 |
Rizzoli, R | 1 |
Brandi, ML | 1 |
Erdal, A | 1 |
Flo, E | 1 |
Aarsland, D | 1 |
Ballard, C | 1 |
Slettebo, DD | 1 |
Husebo, BS | 1 |
McCrae, JC | 1 |
Morrison, EE | 1 |
MacIntyre, IM | 1 |
Dear, JW | 1 |
Webb, DJ | 1 |
Häuser, W | 1 |
Schuler, M | 1 |
Koyuncu, O | 1 |
Hakimoglu, S | 1 |
Ugur, M | 1 |
Akkurt, C | 1 |
Turhanoglu, S | 1 |
Sessler, D | 1 |
Turan, A | 1 |
Saeki, S | 1 |
Rokyta, R | 1 |
Lejčko, J | 1 |
Houdek, K | 1 |
Trefil, L | 1 |
Nedvídek, J | 1 |
Fricová, J | 1 |
Holeček, V | 1 |
Abualnadi, N | 1 |
Dizon, AM | 1 |
Schiff, L | 1 |
Radman, M | 1 |
Babic, A | 1 |
Runjic, E | 1 |
Jelicic Kadic, A | 1 |
Jeric, M | 1 |
Moja, L | 1 |
Davison, SN | 1 |
Yabuki, S | 1 |
Ip, AKK | 1 |
Tam, CK | 1 |
Murakami, T | 1 |
Ushida, T | 1 |
Wang, JH | 1 |
Shin, HK | 1 |
Sun, WZ | 1 |
Williamson, OD | 1 |
Robinson, PJ | 1 |
Rickard, JA | 1 |
Maree, JE | 1 |
Dreyer Wright, SC | 1 |
Makua, MR | 1 |
Yokotsuka, S | 1 |
Kato, J | 1 |
Meyer, CR | 1 |
Farquhar-Smith, P | 1 |
Gubbay, A | 1 |
Bertin, P | 1 |
Becquemont, L | 1 |
Corruble, E | 1 |
Derumeaux, G | 1 |
Falissard, B | 1 |
Hanon, O | 1 |
Pinget, M | 1 |
Forette, F | 1 |
Lee, JH | 1 |
Lee, CS | 1 |
Giese, A | 1 |
Ornek, A | 1 |
Kurucay, M | 1 |
Kilic, L | 1 |
Şendur, SN | 1 |
Münker, A | 1 |
Puchstein, C | 1 |
Lainka, E | 1 |
Wittkowski, H | 1 |
Henning, BF | 1 |
Richette, P | 1 |
McCartney, CJ | 1 |
Nelligan, K | 1 |
Nalamachu, S | 1 |
Schiphorst Preuper, HR | 1 |
Geertzen, JH | 1 |
van Wijhe, M | 1 |
Boonstra, AM | 1 |
Molmans, BH | 1 |
Dijkstra, PU | 1 |
Reneman, MF | 1 |
Meeus, M | 1 |
Hermans, L | 1 |
Ickmans, K | 1 |
Struyf, F | 1 |
Van Cauwenbergh, D | 1 |
Bronckaerts, L | 1 |
De Clerck, LS | 1 |
Moorken, G | 1 |
Hans, G | 1 |
Grosemans, S | 1 |
Nijs, J | 1 |
Cosio, D | 1 |
Sawan, H | 1 |
Chen, AF | 1 |
Viscusi, ER | 1 |
Parvizi, J | 1 |
Hozack, WJ | 1 |
Schreiber, JA | 1 |
Fassoulaki, A | 2 |
Chassiakos, D | 1 |
Melemeni, A | 2 |
Hard, B | 1 |
Bartoli, A | 1 |
Michna, E | 1 |
He, E | 1 |
Wen, W | 1 |
Moore, RA | 2 |
Derry, S | 2 |
Wiffen, PJ | 2 |
Straube, S | 1 |
Aldington, DJ | 1 |
Malec, M | 1 |
Shega, JW | 1 |
Fulton, RL | 1 |
Walters, MR | 1 |
Morton, R | 1 |
Touyz, RM | 1 |
Dominiczak, AF | 1 |
Morrison, DS | 1 |
Padmanabhan, S | 1 |
Meredith, PA | 1 |
McInnes, GT | 1 |
Dawson, J | 1 |
Glasser, SP | 1 |
Khodneva, Y | 1 |
Nuseir, KQ | 1 |
Alzoubi, KH | 1 |
Alabwaini, J | 1 |
Khabour, OF | 1 |
Kassab, MI | 1 |
Kurita Varoli, F | 1 |
Sucena Pita, M | 1 |
Sato, S | 1 |
Issa, JP | 1 |
do Nascimento, C | 1 |
Pedrazzi, V | 1 |
Zheng, Y | 1 |
Kostenbader, K | 1 |
Barrett, T | 2 |
Hisaw, E | 1 |
Giuliani, MJ | 1 |
Chen, Y | 1 |
Young, JL | 2 |
Dale, O | 1 |
Borchgrevink, PC | 1 |
Fredheim, OM | 1 |
Mahic, M | 1 |
Romundstad, P | 1 |
Skurtveit, S | 1 |
Eisenhauer, TD | 1 |
Matchett, M | 1 |
Heasley, R | 1 |
Morton, T | 1 |
Devarakonda, K | 1 |
Giuliani, M | 1 |
Hoban, B | 1 |
Larance, B | 1 |
Gisev, N | 1 |
Nielsen, S | 1 |
Cohen, M | 1 |
Bruno, R | 1 |
Shand, F | 1 |
Lintzeris, N | 1 |
Hall, W | 1 |
Farrell, M | 1 |
Degenhardt, L | 1 |
Nielsen, RV | 1 |
Siegel, H | 1 |
Fomsgaard, JS | 1 |
Andersen, JDH | 1 |
Martusevicius, R | 1 |
Mathiesen, O | 1 |
Dahl, JB | 1 |
Yoshizawa, K | 1 |
Kawai, K | 1 |
Fujie, M | 1 |
Suzuki, J | 1 |
Ogawa, Y | 1 |
Yajima, T | 1 |
Yokomori, J | 1 |
Ennis, ZN | 1 |
Dideriksen, D | 1 |
Vaegter, HB | 1 |
Handberg, G | 1 |
Pottegård, A | 1 |
Bugada, D | 1 |
Lavand'homme, P | 1 |
Ambrosoli, AL | 1 |
Cappelleri, G | 1 |
Saccani Jotti, GM | 1 |
Meschi, T | 1 |
Fanelli, G | 1 |
Allegri, M | 1 |
Rapo-Pylkkö, S | 1 |
Haanpää, M | 1 |
Liira, H | 1 |
Lawrence, R | 1 |
Källén, B | 1 |
Reis, M | 1 |
Motov, SM | 1 |
Nelson, LS | 1 |
Mo, L | 1 |
Liang, D | 1 |
Madden, A | 1 |
Aung, AK | 1 |
Tetsunaga, T | 2 |
Tanaka, M | 1 |
Nishida, K | 1 |
Takei, Y | 1 |
Ozaki, T | 1 |
Hultzsch, S | 1 |
Schaefer, C | 1 |
Knaggs, R | 1 |
Cole, P | 1 |
Phillips, T | 1 |
Chou, R | 1 |
Deyo, R | 1 |
Friedly, J | 1 |
Skelly, A | 1 |
Weimer, M | 1 |
Fu, R | 1 |
Dana, T | 1 |
Kraegel, P | 1 |
Griffin, J | 1 |
Grusing, S | 1 |
Nawai, A | 1 |
Leveille, SG | 1 |
Shmerling, RH | 1 |
van der Leeuw, G | 1 |
Bean, JF | 1 |
Kesiktas, N | 1 |
Karakas, S | 1 |
Gun, K | 1 |
Gun, N | 1 |
Murat, S | 1 |
Uludag, M | 1 |
O'Connor, ES | 1 |
Schwarze, ML | 1 |
Kodner, IJ | 1 |
Keune, JD | 1 |
Du, Y | 1 |
Ellert, U | 1 |
Zhuang, W | 1 |
Knopf, H | 1 |
Derbent, A | 1 |
Yilmaz, B | 1 |
Uyar, M | 1 |
Woitzek, K | 1 |
Park, SC | 1 |
Kim, KH | 1 |
Tsaroucha, A | 1 |
Paraskeva, A | 1 |
Pellicano, R | 1 |
Guerra, L | 1 |
Labianca, R | 1 |
Sarzi-Puttini, P | 1 |
Zuccaro, SM | 1 |
Cherubino, P | 1 |
Fornasari, D | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
N-of-1 Trials Using mHealth in Chronic Pain Aka PREEMPT (Personalized Research for Monitoring Pain Treatment)[NCT02116621] | 215 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
Efficacy of Different Doses of Pregabalin as a Multimodal Analgesic Agent in Postoperative Pain Control After Total Knee Arthroplasty - A Randomized Controlled Trial[NCT05447364] | Phase 4 | 82 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | ||
Patient-centered Treatment of Anxiety After Low-Risk Chest Pain in the Emergency Room[NCT04811521] | 375 participants (Anticipated) | Interventional | 2021-04-01 | Enrolling by invitation | |||
Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) Trial[NCT01583985] | 265 participants (Actual) | Interventional | 2013-06-01 | Completed | |||
Video-based, Patient-Focused Opioid Education in the Perioperative Period: A Feasibility Study[NCT03986866] | 110 participants (Actual) | Interventional | 2019-04-29 | Completed | |||
Achieving Peri-Operative Pain Control Without Opioids[NCT04813991] | Phase 3 | 0 participants (Actual) | Interventional | 2022-03-15 | Withdrawn (stopped due to Enrollment was never initiated and the PI is leaving the institution so the study is closing.) | ||
Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial.[NCT02267057] | Phase 4 | 163 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
National Observatory on the Therapeutic Management in Ambulatory Care Patients Aged 65 and Over, With Diabetes Type 2, Chronic Pain or Atrial Fibrillation[NCT01065909] | 3,491 participants (Actual) | Observational | 2009-05-31 | Completed | |||
A Randomized, Placebo-Controlled, Parallel Group, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Tramadol HCl/Acetaminophen Extended Release Tablet in Subjects With Chronic Low Back Pain[NCT01112267] | Phase 3 | 248 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
Opioid-Free Shoulder Arthroplasty[NCT03540030] | Phase 4 | 86 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
Efficacy and Side Effects of Intrathecal Morphine in Multimodal Analgesia for Unilateral Total Knee Arthroplasty[NCT03232957] | 131 participants (Actual) | Interventional | 2017-08-01 | Completed | |||
Effect of Paracetamol and Ibuprofen When Intravenously Given Combination or Alone in Reducing Morphine Requirements After Total Knee Arthroplasty[NCT04414995] | Phase 2/Phase 3 | 36 participants (Actual) | Interventional | 2020-06-05 | Completed | ||
Evaluating Change in Back Pain From Access to a Sit-stand Workstation[NCT02146482] | 57 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
Unraveling Impaired Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes: a Series of Experiments Targeting Brain Neurotransmission[NCT01154647] | 70 participants (Anticipated) | Interventional | 2010-09-30 | Not yet recruiting | |||
Hypoalgesic Effect of Median Nerve Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02596815] | 51 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
Hypoalgesic Effect of Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group[NCT02595294] | 52 participants (Actual) | Interventional | 2015-07-31 | Completed | |||
Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain[NCT02593721] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
Randomized Double-blind Controlled Study to Assess the Efficacy of Intravenous Acetaminophen Associated With Strong Opioids in the Management of Acute Pain in Adult Cancer Patients[NCT04779567] | Phase 4 | 112 participants (Actual) | Interventional | 2019-06-10 | Completed | ||
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain[NCT01722864] | Phase 3 | 153 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen as Adjuvant, Postoperative Pain After Herniated Disc Surgery[NCT01953978] | Phase 4 | 160 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
A Combination Study With Sub-Dissociative Ketamine and Fentanyl to Treat Moderate to Severe Pain in the Emergency Department[NCT03959852] | Phase 4 | 6 participants (Actual) | Interventional | 2019-11-18 | Terminated (stopped due to Residency completed.) | ||
Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial.[NCT04704297] | Phase 4 | 180 participants (Anticipated) | Interventional | 2020-12-28 | Recruiting | ||
Electroacupuncture Frequency-related Effects on Chronic Low Back Pain in Older Adults: Triple-blind, 12-month Protocol for a Randomized Controlled Trial.[NCT03802045] | 125 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | |||
Determining the Effectiveness of the Geriatric Pain Measure ın Older Adults Attending a Gynecology Clinic[NCT04789590] | 100 participants (Actual) | Observational | 2018-08-01 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Four questions from the Pain Medication in Primary Care Patient Questionnaire measured adherence to medications at baseline and 13 weeks. Two questions comprised a subscale assessing overuse of medications. Overuse scores range from 0 - 100. Higher scores indicate greater adherence and less overuse of medications. Data table measures show change over time with positive numbers indicating greater adherence (less overuse of medications) and negative numbers indicating less adherence. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 1.40 |
Control-Usual Care | 0.35 |
Four questions from the Pain Medication in Primary Care Patient Questionnaire measured adherence to medications at baseline and 26 weeks. Two questions comprised a subscale assessing overuse of medications. Overuse scores range from 0 - 100. Higher scores indicate greater adherence and less overuse of medications. Data table measures show change over time with positive numbers indicating greater adherence (less overuse of medications) and negative numbers indicating less adherence. (NCT02116621)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 1.77 |
Control-Usual Care | -0.13 |
Four questions from the Pain Medication in Primary Care Patient Questionnaire measured adherence to medications at baseline and 52 weeks. Two questions comprised a subscale assessing overuse of medications. Overuse scores range from 0 - 100. Higher scores indicate greater adherence and less overuse of medications. Data table measures show change over time with positive numbers indicating greater adherence (less overuse of medications) and negative numbers indicating less adherence. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 1.61 |
Control-Usual Care | 1.53 |
Four questions from the Pain Medication in Primary Care Patient Questionnaire measured adherence to medications at baseline and 13 weeks. Two questions comprised a subscale assessing underuse of medications. Underuse scores range from 0-100. Higher scores indicate greater adherence and less underuse of medication. Data table measures show change over time with positive numbers indicating greater adherence (less underuse of medications) and negative numbers indicating less adherence. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 2.53 |
Control-Usual Care | -1.71 |
Four questions from the Pain Medication in Primary Care Patient Questionnaire measured adherence to medications at baseline and 26 weeks. Two questions comprised a subscale assessing underuse of medications. Underuse scores range from 0-100. Higher scores indicate greater adherence and less underuse of medication. Data table measures show change over time with positive numbers indicating greater adherence (less underuse of medications) and negative numbers indicating less adherence. (NCT02116621)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 1.88 |
Control-Usual Care | -2.76 |
Four questions from the Pain Medication in Primary Care Patient Questionnaire measured adherence to medications at baseline and 52 weeks. Two questions comprised a subscale assessing underuse of medications. Underuse scores range from 0-100. Higher scores indicate greater adherence and less underuse of medication. Data table measures show change over time with positive numbers indicating greater adherence (less underuse of medications) and negative numbers indicating less adherence. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -3.53 |
Control-Usual Care | -1.62 |
Pain intensity measured with Patient-Reported Outcomes Measurement Information System (PROMIS) 3a short form at baseline and 13 weeks, which measures self-reported estimate of how much a person hurts. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Pain intensity scores range from 0 - 100. For pain intensity, higher scores indicate greater pain intensity. Data table measures show change over time with negative numbers indicating improvement (decreases) and positive numbers indicating increases in pain intensity. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -1.60 |
Control-Usual Care | -1.92 |
Pain intensity measured with Patient-Reported Outcomes Measurement Information System (PROMIS) 3a short form at baseline and 26 weeks, which measures self-reported estimate of how much a person hurts. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Pain intensity scores range from 0 - 100. For pain intensity, higher scores indicate greater pain intensity. Data table measures show change over time with negative numbers indicating improvement (decreases) and positive numbers indicating increases in pain intensity. (NCT02116621)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -2.86 |
Control-Usual Care | -1.46 |
Pain intensity measured with Patient-Reported Outcomes Measurement Information System (PROMIS) 3a short form at baseline and 52 weeks, which measures self-reported estimate of how much a person hurts. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Pain intensity scores range from 0 - 100. For pain intensity, higher scores indicate greater pain intensity. Data table measures show change over time with negative numbers indicating improvement (decreases) and positive numbers indicating increases in pain intensity. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -3.00 |
Control-Usual Care | -1.76 |
Pain interference measured with Patient Reported Outcomes Measurement Information System (PROMIS) Scale 8-item short form at baseline and 26 weeks which measures self-reported consequences of pain on relevant aspects of one's life. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Pain interference scores range from 0 - 100. For pain interference, higher scores indicate greater pain interference. Data table measures show change over time with negative numbers indicating improvement (decreases) and positive numbers indicating increases in pain interference. (NCT02116621)
Timeframe: baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -3.22 |
Control-Usual Care | -1.85 |
Pain-related interference measured with Patient-Reported Outcomes Measurement Information System (PROMIS) 8-item short form at baseline and 13 weeks which measures self-reported consequences of pain on relevant aspects of one's life. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Pain interference scores range from 0 - 100. For pain interference, higher scores indicate greater pain interference. Data table measures show change over time with negative numbers indicating improvement (decreases) and positive numbers indicating increases in pain interference. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -2.70 |
Control-Usual Care | -1.91 |
Pain-related interference measured with Patient-Reported Outcomes Measurement Information System (PROMIS) 8-item short form at baseline and 52 weeks which measures self-reported consequences of pain on relevant aspects of one's life. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Pain interference scores range from 0 - 100. For pain interference, higher scores indicate greater pain interference. Data table measures show change over time with negative numbers indicating improvement (decreases) and positive numbers indicating increases in pain interference. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -2.67 |
Control-Usual Care | -2.83 |
Four questions from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey assessed patient-provider discussions on starting/stopping medications and comprise medication related shared decision making. Scores were computed only for patients who reported discussing medications with their clinician in the past 12 months. Medication related shared decision making scores range from 0-100. Higher scores indicate more shared decision making. (NCT02116621)
Timeframe: 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 79.6 |
Control-Usual Care | 67.7 |
Four questions from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey assessed patient-provider discussions on starting/stopping medications and comprise medication related shared decision making. Scores were computed only for patients who reported discussing medications with their clinician in the past 12 months. Medication related shared decision making scores range from 0-100. Higher scores indicate more shared decision making. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 74.8 |
Control-Usual Care | 65.4 |
Patient trust in physician measured with 11-item Trust in Physician Scale at baseline and 13 weeks to assess the quality of the patient-clinician relationship. Trust in physician scores range from 0 - 100. Higher scores indicate greater patient trust in the clinician providing pain treatment. Data table measures show change over time with positive numbers indicating increases in trust and negative numbers indicating declines in trust. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -2.49 |
Control-Usual Care | -4.25 |
Patient trust in physician measured with 11-item Trust in Physician Scale at baseline and 26 weeks to assess the quality of the patient-clinician relationship. Trust in physician scores range from 0 - 100. Higher scores indicate greater patient trust in the clinician providing pain treatment. Data table measures show change over time with positive numbers indicating increases in trust and negative numbers indicating declines in trust. (NCT02116621)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -2.30 |
Control-Usual Care | -4.84 |
Patient trust in physician measured with 11-item Trust in Physician Scale at baseline and 52 weeks to assess the quality of the patient-clinician relationship. Trust in physician scores range from 0 - 100. Higher scores indicate greater patient trust in the clinician providing pain treatment. Data table measures show change over time with positive numbers indicating increases in trust and negative numbers indicating declines in trust. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -4.00 |
Control-Usual Care | -5.53 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline and 13 weeks, creating three subscales. Satisfaction with medical care is a subscale that includes 5 questions assessing medical care for pain. Satisfaction with medical care scores range from 0 - 100. Higher scores indicate greater patient satisfaction with medical care. Data table measures show change over time with positive numbers indicating increases in satisfaction with medical care and negative numbers indicating declines in patient satisfaction. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -4.00 |
Control-Usual Care | -6.15 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline and 26 weeks, creating three subscales. Satisfaction with medical care is a subscale that includes 5 questions assessing medical care for pain. Satisfaction with medical care scores range from 0 - 100. Higher scores indicate greater patient satisfaction with medical care. Data table measures show change over time with positive numbers indicating increases in satisfaction with medical care and negative numbers indicating declines in patient satisfaction. (NCT02116621)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -2.26 |
Control-Usual Care | -5.57 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline and 52 weeks, creating three subscales. Satisfaction with medical care is a subscale that includes 5 questions assessing medical care for pain. Satisfaction with medical care scores range from 0 - 100. Higher scores indicate greater patient satisfaction with medical care. Data table measures show change over time with positive numbers indicating increases in satisfaction with medical care and negative numbers indicating declines in patient satisfaction. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -4.52 |
Control-Usual Care | -5.51 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline and 13 weeks, creating three subscales. Satisfaction with pain information is a subscale that includes 5 questions assessing information about pain and its treatment. Satisfaction with pain information range from 0-100. Higher scores indicate greater patient satisfaction with information received about pain and treatment for pain. Data table measures show change over time with positive numbers indicating increases in satisfaction with pain information and negative numbers indicating declines in patient satisfaction. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 4.41 |
Control-Usual Care | -3.36 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline and 26 weeks, creating three subscales. Satisfaction with pain information is a subscale that includes 5 questions assessing information about pain and its treatment. Satisfaction with pain information range from 0-100. Higher scores indicate greater patient satisfaction with information received about pain and treatment for pain. Data table measures show change over time with positive numbers indicating increases in satisfaction with pain information and negative numbers indicating declines in patient satisfaction. (NCT02116621)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 11.28 |
Control-Usual Care | 3.99 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline and 52 weeks, creating three subscales. Satisfaction with pain information is a subscale that includes 5 questions assessing information about pain and its treatment. Satisfaction with pain information range from 0-100. Higher scores indicate greater patient satisfaction with information received about pain and treatment for pain. Data table measures show change over time with positive numbers indicating increases in satisfaction with pain information and negative numbers indicating declines in patient satisfaction. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 9.02 |
Control-Usual Care | 4.89 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline and 13 weeks, creating three subscales. Satisfaction with current pain medication is a subscale that includes 8 questions assessing current pain medications. Satisfaction with pain medication scores range from 0-100. Higher scores indicate greater patient satisfaction with current pain medications. Data table measures show change over time with positive numbers indicating increases in satisfaction with pain medications and negative numbers indicating declines in satisfaction with pain medications. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 1.46 |
Control-Usual Care | -0.34 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline and 26 weeks, creating three subscales. Satisfaction with current pain medication is a subscale that includes 8 questions assessing current pain medications. Satisfaction with pain medication scores range from 0-100. Higher scores indicate greater patient satisfaction with current pain medications. Data table measures show change over time with positive numbers indicating increases in satisfaction with pain medications and negative numbers indicating declines in satisfaction with pain medications. (NCT02116621)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -0.18 |
Control-Usual Care | 1.39 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline and 52 weeks, creating three subscales. Satisfaction with current pain medication is a subscale that includes 8 questions assessing current pain medications. Satisfaction with pain medication scores range from 0-100. Higher scores indicate greater patient satisfaction with current pain medications. Data table measures show change over time with positive numbers indicating increases in satisfaction with pain medications and negative numbers indicating declines in satisfaction with pain medications. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 0.77 |
Control-Usual Care | -0.34 |
Global health measured with 10 item Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale at baseline and 13 weeks, representing physical and mental health components. Global mental health measures mental health, quality of life, satisfaction with social activities and emotional problems. The final mental health score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Global mental health scores range from 0 - 100, and higher scores indicate better mental health. Data table measures show change over time with positive numbers indicating improvement in global mental health and negative numbers indicating declines in global mental health. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | -0.35 |
Control-Usual Care | 0.30 |
Global health measured with 10 item Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale at baseline and 26 weeks, representing physical and mental health components. Global mental health measures mental health, quality of life, satisfaction with social activities and emotional problems. The final mental health score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Global mental health scores range from 0 - 100, and higher scores indicate better mental health. Data table measures show change over time with positive numbers indicating improvement in global mental health and negative numbers indicating declines in global mental health. (NCT02116621)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 0.21 |
Control-Usual Care | -0.72 |
Global health measured with 10 item Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale at baseline and 52 weeks, representing physical and mental health components. Global mental health measures mental health, quality of life, satisfaction with social activities and emotional problems. The final mental health score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Global mental health scores range from 0 - 100, and higher scores indicate better mental health. Data table measures show change over time with positive numbers indicating improvement in global mental health and negative numbers indicating declines in global mental health. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 0.36 |
Control-Usual Care | -0.39 |
Global health measured with 10 item Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale at baseline and 13 weeks, representing physical and mental health components. Global physical health measures overall physical health, physical function, pain and fatigue. The final physical health score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Physical global health scores range from 0 - 100, and higher scores indicate better physical health. Data table measures show change over time with positive numbers indicating improvement in global physical health and negative numbers indicating declines in global physical health. (NCT02116621)
Timeframe: Baseline, 13 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 0.73 |
Control-Usual Care | 0.44 |
Global health measured with 10 item Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale at baseline and 26 weeks, representing physical and mental health components. Global physical health measures overall physical health, physical function, pain and fatigue. The final physical health score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Physical global health scores range from 0 - 100, and higher scores indicate better physical health. Data table measures show change over time with positive numbers indicating improvement in global physical health and negative numbers indicating declines in global physical health. (NCT02116621)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 0.13 |
Control-Usual Care | 0.30 |
Global health measured with 10 item Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale at baseline and 52 weeks, representing physical and mental health components. Global physical health measures overall physical health, physical function, pain and fatigue. The final physical health score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Physical global health scores range from 0 - 100, and higher scores indicate better physical health. Data table measures show change over time with positive numbers indicating improvement in global physical health and negative numbers indicating declines in global physical health. (NCT02116621)
Timeframe: Baseline, 52 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
Trialist Intervention | 0.16 |
Control-Usual Care | 0.42 |
Four questions from the Pain Medication in Primary Care Patient Questionnaire measured adherence to medications at baseline, 13 weeks, 26 weeks, 52 weeks. Two questions comprised a subscale assessing overuse of medications. Overuse scores range from 0 - 100. Higher scores indicate greater adherence and less overuse of medications. Data table measures show change over time with positive numbers indicating greater adherence (less overuse of medications) and negative numbers indicating less adherence. (NCT02116621)
Timeframe: Baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | 0.35 | -0.13 | 1.53 |
Trialist Intervention | 1.40 | 1.77 | 1.61 |
Four questions from the Pain Medication in Primary Care Patient Questionnaire measured adherence to medications at baseline, 13 weeks, 26 weeks, 52 weeks. Two questions comprised a subscale assessing underuse of medications. Underuse scores range from 0-100. Higher scores indicate greater adherence and less underuse of medication. Data table measures show change over time with positive numbers indicating greater adherence (less underuse of medications) and negative numbers indicating less adherence. (NCT02116621)
Timeframe: baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | -1.71 | -2.76 | -1.62 |
Trialist Intervention | 2.53 | 1.88 | -3.53 |
Pain intensity measured with Patient-Reported Outcomes Measurement Information System (PROMIS) 3a short form at baseline, 13 weeks, 26 weeks, and 52 weeks which measures self-reported estimate of how much a person hurts. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Pain intensity scores range from 0 - 100. For pain intensity, higher scores indicate greater pain intensity. Data table measures show change over time with negative numbers indicating improvement (decreases) and positive numbers indicating increases in pain intensity. (NCT02116621)
Timeframe: baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | -1.92 | -1.46 | -1.76 |
Trialist Intervention | -1.60 | -2.86 | -3.00 |
Pain-related Interference measured with Patient-Reported Outcomes Measurement Information System (PROMIS) scale 8-item short form at baseline, 13 weeks, 26 weeks, and 52 weeks which measures self-reported consequences of pain on relevant aspects of one's life. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Pain interference scores range from 0 - 100. For pain interference, higher scores indicate greater pain interference. Data table measures show change over time with negative numbers indicating improvement (decreases) and positive numbers indicating increases in pain interference. (NCT02116621)
Timeframe: baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | -1.91 | -1.85 | -2.83 |
Trialist Intervention | -2.70 | -3.22 | -2.67 |
Patient trust in physician measured with 11-item Trust in Physician Scale at baseline, 13 weeks, 26 weeks, and 52 weeks to assess the quality of the patient-clinician relationship. Trust in physician scores range from 0 - 100. Higher scores indicate greater patient trust in the clinician providing pain treatment. Data table measures show change over time with positive numbers indicating increases in trust and negative numbers indicating declines in trust. (NCT02116621)
Timeframe: baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | -4.25 | -4.84 | -5.53 |
Trialist Intervention | -2.49 | -2.30 | -4.00 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline, 13 weeks, 26 weeks, 52 weeks, creating three subscales. Satisfaction with medical care is a subscale that includes 5 questions assessing medical care for pain. Satisfaction with medical care scores range from 0 - 100. Higher scores indicate greater patient satisfaction with medical care. Data table measures show change over time with positive numbers indicating increases in satisfaction with medical care and negative numbers indicating declines in patient satisfaction. (NCT02116621)
Timeframe: Baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | -6.15 | -5.57 | -5.51 |
Trialist Intervention | -4.00 | -2.26 | -4.52 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline, 13 weeks, 26 weeks, and 52 weeks, creating three subscales. Satisfaction with pain information is a subscale that includes 5 questions assessing information about pain and its treatment. Satisfaction with pain information range from 0-100. Higher scores indicate greater patient satisfaction with information received about pain and treatment for pain. Data table measures show change over time with positive numbers indicating increases in satisfaction with pain information and negative numbers indicating declines in patient satisfaction. (NCT02116621)
Timeframe: Baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | -3.36 | 3.99 | 4.89 |
Trialist Intervention | 4.41 | 11.28 | 9.02 |
The Pain Treatment Satisfaction Scale consists of 18 items assessing patient satisfaction at baseline, 13 weeks, 26 weeks, 52 weeks, creating three subscales. Satisfaction with current pain medication is a subscale that includes 8 questions assessing current pain medications. Satisfaction with pain medication scores range from 0-100. Higher scores indicate greater patient satisfaction with current pain medications. Data table measures show change over time with positive numbers indicating increases in satisfaction with pain medications and negative numbers indicating declines in satisfaction with pain medications. (NCT02116621)
Timeframe: Baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | -0.34 | 1.39 | -0.34 |
Trialist Intervention | 1.46 | -0.18 | 0.77 |
Global health measured with 10 item Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale at baseline, 13 weeks, 26 weeks, and 52 weeks, representing physical and mental health components. Global mental health measures mental health, quality of life, satisfaction with social activities and emotional problems. The final mental health score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Global mental health scores range from 0 - 100, and higher scores indicate better mental health. Data table measures show change over time with positive numbers indicating improvement in global mental health and negative numbers indicating declines in global mental health. (NCT02116621)
Timeframe: baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | 0.30 | -0.72 | -0.39 |
Trialist Intervention | -0.35 | 0.21 | 0.36 |
Global health measured with 10 item Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale at baseline, 13 weeks, 26 weeks, 52 weeks, representing physical and mental health components. Global physical health measures overall physical health, physical function, pain and fatigue. The final physical health score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation of 10. Physical global health scores range from 0 - 100, and higher scores indicate better physical health. Data table measures show change over time with positive numbers indicating improvement in global physical health and negative numbers indicating declines in global physical health. (NCT02116621)
Timeframe: baseline, 13 weeks, 26 weeks, 52 weeks
Intervention | units on a scale (Least Squares Mean) | ||
---|---|---|---|
Change from baseline to 13 weeks | Change from baseline to 26 weeks | Change from baseline to 52 weeks | |
Control-Usual Care | 0.44 | 0.30 | 0.42 |
Trialist Intervention | 0.73 | 0.13 | 0.16 |
Measure of pain-related functional interference (range 0-10; higher score is worse) (NCT01583985)
Timeframe: 3 months, 6 months, 9 months, and 12 months
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
3 months | 6 months | 9 months | 12 months | |
Non-opioid | 3.7 | 3.6 | 3.3 | 3.3 |
Opioid | 3.7 | 3.4 | 3.6 | 3.4 |
Measure of pain intensity (range 0-10; higher score is worse) (NCT01583985)
Timeframe: 3 months, 6 months, 9 months, and 12 months
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
3 months | 6 months | 9 months | 12 months | |
Non-opioid | 4.0 | 4.1 | 3.6 | 3.5 |
Opioid | 4.3 | 4.1 | 4.2 | 4.0 |
Checklist of bothersome medication-related symptoms (0-19, higher number = more symptoms) (NCT01583985)
Timeframe: 3 months, 6 months, 9 months, and 12 months
Intervention | symptoms (Mean) | |||
---|---|---|---|---|
3 months | 6 months | 9 months | 12 months | |
Non-opioid | 1.3 | 1.3 | 0.9 | 0.9 |
Opioid | 2.3 | 2.1 | 1.9 | 1.8 |
Feasibility of collecting data on the percentage of patients who develop chronic opioid use. This is measured as the number of patients who received an opioid prescription per the Arkansas prescription drug monitoring database during the 90-150 day period post operatively. (NCT03986866)
Timeframe: 90-150 days
Intervention | Participants (Count of Participants) |
---|---|
No Video | 12 |
Video | 5 |
Knowledge of Post operative Opioids after surgery via 7 day post operative phone call. Knowledge is measured on a scale of 1 to 10 with 10 being complete knowledge and 1 being no knowledge. (NCT03986866)
Timeframe: 7 days
Intervention | units on a scale (Mean) |
---|---|
No Video | 8.32 |
Video | 9.36 |
Post-operative pain control as determined by opioid utilization at three months. This is the number of patients that have discontinued opioids at the 3 month mark. (NCT03986866)
Timeframe: Up to 3 months
Intervention | Participants (Count of Participants) |
---|---|
No Video | 47 |
Video | 38 |
Feasibility of collecting data on the number of days until opioid cessation (NCT03986866)
Timeframe: Up to 3 months
Intervention | days (Mean) |
---|---|
No Video | 13.9 |
Video | 13.9 |
"Global assessment on investigational product was done by investigator on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than Good was considered as pain improvement success. Percentage of participants with pain improvement success is reported here." (NCT01112267)
Timeframe: Day 29
Intervention | Percentage of participants (Number) |
---|---|
Tramadol HCl/Acetaminophen | 81.25 |
Placebo | 69.88 |
"Global assessment on investigational product was done by participants on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than Good was considered as pain improvement success. Percentage of participants with pain improvement success is reported here." (NCT01112267)
Timeframe: Day 29
Intervention | Percentage of participants (Number) |
---|---|
Tramadol HCl/Acetaminophen | 76.25 |
Placebo | 72.29 |
The percentage of participants with extent of reduction in pain intensity greater than or equal to 30 percent was reported. Pain intensity change rate was calculated by Visual Analog Scale (VAS) score at baseline minus VAS score at Day 29 divided by VAS score at Baseline. VAS is a 10 centimeter (cm) scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain. (NCT01112267)
Timeframe: Baseline up to Day 29
Intervention | Percentage of Participants (Number) |
---|---|
Tramadol HCl/Acetaminophen | 57.65 |
Placebo | 41.11 |
The ODI Korean version was used to assess the participant's functionality. The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). Total score is the sum of score obtained in each section and ranges from 0 to 50. A higher score represents greater disability. (NCT01112267)
Timeframe: Baseline and Day 29
Intervention | Unit on a scale (Mean) | |
---|---|---|
Baseline | Change at Day 29 (n=87,83) | |
Placebo | 38.126 | 7.178 |
Tramadol HCl/Acetaminophen | 39.626 | 11.216 |
Change in pain intensity experienced by participants over the last 48 hours was measured on Day 29 against Baseline with VAS. VAS is a 10 cm scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain. (NCT01112267)
Timeframe: Baseline and Day 29
Intervention | Unit on a scale (Mean) | |
---|---|---|
Baseline | Change at Day 29 | |
Placebo | 6.000 | 1.549 |
Tramadol HCl/Acetaminophen | 6.334 | 2.299 |
"The quality of life of participants was evaluated by SF-36 Korean version questionnaire. It is composed of 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Participants answered to the questionnaire of 36 questions; and physical, social, and psychological health status were assessed. It ranges 0 to 100, and higher score indicates better quality of life, But in Reported (Rptd.) Health Transition domain higher score indicates worse quality of life." (NCT01112267)
Timeframe: Baseline and Day 29
Intervention | Unit on a scale (Mean) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline: Physical functioning | Change at Day 29: Physical functioning (n=83,87) | Baseline: Role physical | Change at Day 29: Role Physical (n=83,87) | Baseline: Bodily pain | Change at Day 29: Bodily pain (n=83,87) | Baseline: General health | Change at Day 29: General health (n=83,87) | Baseline: Vitality | Change at Day 29: Vitality (n=83,87) | Baseline: Social functioning | Change at Day 29: Social functioning (n=83,87) | Baseline: Role emotional | Change at Day 29: Role emotional (n=83,87) | Baseline: Mental Health | Change at Day 29: Mental Health (n=83,87) | Baseline: Rptd. health transition | Change at Day 29: Rptd. health transition(n=83,87) | |
Placebo | 47.94 | 6.67 | 49.51 | 8.69 | 35.99 | 17.69 | 48.11 | 2.77 | 42.71 | 5.82 | 64.58 | 6.61 | 61.57 | 7.47 | 60.56 | 18.39 | 63.61 | -6.90 |
Tramadol HCl/Acetaminophen | 46.71 | 9.82 | 44.93 | 16.04 | 34.66 | 19.39 | 43.56 | 7.36 | 38.82 | 11.14 | 64.26 | 11.75 | 61.76 | 8.13 | 61.06 | 20.48 | 65.00 | -18.07 |
Pain relief was measured in 6 stages to assess the participant's pain relief. Extent of pain relief was measured on a scale ranging from 4 to -1, where 4=complete disappearance, 3=fair relief, 2=moderate relief, 1=slight relief, 0=no change and -1=pain worsening. Relief more than 'slight relief (1)' was considered as pain relief success. (NCT01112267)
Timeframe: Day 8, Day 15 and Day 29
Intervention | Percentage of participants (Number) | ||
---|---|---|---|
Day 8: Slight relief (n=82,88) | Day 15: Slight relief (n=85,89) | Day 29, Slight relief (85,89) | |
Placebo | 53.41 | 65.17 | 77.53 |
Tramadol HCl/Acetaminophen | 70.73 | 82.35 | 81.18 |
American Shoulder and Elbow Surgeons (ASES) Shoulder Score for pain and function. Range 0-100. Low score = worse shoulder condition. Function, disability, and pain subscores (all ranges 0-50), and are summed for total ASES score. (NCT03540030)
Timeframe: 2 Weeks
Intervention | units on a scale (Median) |
---|---|
Observational | 54.3 |
Non-Opioid Intervention | 54.2 |
Morphine milli-equivalents In-hospital post-operative. Continuous scale of MME, no defined better/worse. Measured as number and dose of medications taken. For example, if the patient received an opioid, the drug and dose was recorded and converted to MME. A time frame of when to assess opioid use in-hospital post-operative was not used but was a continuous monitor for rescue opioid from in-hospital post-operative through discharge. (NCT03540030)
Timeframe: In-hospital Stay
Intervention | Morphine milli-equivalents (Median) |
---|---|
Observational | 45.0 |
Non-Opioid Intervention | 19.0 |
Pain at patient discharge or 24-hours, whichever comes first - measured on a 0 (no pain) -10 (worst possible pain) numeric rating scale (NRS). A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 24 hours
Intervention | score on a scale (Median) |
---|---|
Observational | 3.0 |
Non-Opioid Intervention | 2.0 |
Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Months
Intervention | score on a scale (Median) |
---|---|
Observational | 6 |
Non-Opioid Intervention | 6 |
Simple Shoulder Test (SST) activity score. Range 0-12. 0 = worse activity score. (NCT03540030)
Timeframe: 2 Weeks
Intervention | score on a scale (Median) |
---|---|
Observational | 2.0 |
Non-Opioid Intervention | 2.0 |
post-operative pain: measured on a 0 (no pain) -10 (worst) numeric rating scale (NRS) at 6hrs, 12hrs, 2 weeks, and 2 months. A score of 0(no pain) is preferable to 10(worst possible pain) (NCT03540030)
Timeframe: 6hrs, 12hrs, 2weeks, 2 months
Intervention | score on a scale (Median) | |||
---|---|---|---|---|
6 Hrs | 12 hrs | 2 weeks | 2 months | |
Non-Opioid Intervention | 0.0 | 0 | 0.82 | 0 |
Observational | 2 | 4 | 1.3 | 0.7 |
rate of constipation (NCT03540030)
Timeframe: 2 Months
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Yes | No | Unknown | |
Non-Opioid Intervention | 4 | 27 | 4 |
Observational | 7 | 21 | 2 |
rate of constipation (NCT03540030)
Timeframe: 2 Weeks
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Yes | No | Unknown | |
Non-Opioid Intervention | 13 | 22 | 0 |
Observational | 19 | 9 | 2 |
rate of falls (NCT03540030)
Timeframe: 2 Months
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Yes | No | Unknown | |
Non-Opioid Intervention | 4 | 27 | 4 |
Observational | 4 | 24 | 2 |
rate of falls (NCT03540030)
Timeframe: 2 Weeks
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Yes | No | Unknown | |
Non-Opioid Intervention | 5 | 30 | 0 |
Observational | 1 | 27 | 2 |
rate of nausea (NCT03540030)
Timeframe: 2 Months
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Yes | No | Unknown | |
Non-Opioid Intervention | 1 | 30 | 0 |
Observational | 0 | 28 | 2 |
rate of nausea (NCT03540030)
Timeframe: 2 Weeks
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Yes | No | Unknown | |
Non-Opioid Intervention | 1 | 34 | 0 |
Observational | 5 | 23 | 2 |
Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Months
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Yes | No | Unknown | |
Non-Opioid Intervention | 29 | 2 | 4 |
Observational | 23 | 5 | 2 |
Satisfaction with overall pain using Numeric Pain Rating (NRS) scale. yes, no. No being better than yes. (NCT03540030)
Timeframe: 2 Weeks
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
Yes | No | Unknown | |
Non-Opioid Intervention | 34 | 1 | 0 |
Observational | 27 | 1 | 2 |
quality of life using VR-12 subscores. Physical Health (PCS) subscore and Mental Health (MCS) subscore, not summed. Range reported in weighted units. Physical Health subscore: 1 point increase in PCS is associated with 6% lower total health care expenditures, 5% lower pharmacy expenditures, 9% lower rate of hospital inpatient visits, 4% lower rate of medical provider visits, 5% lower rate of hospital outpatient visits. Mental Health sub score a 1 point increase in MCS is associated with 7% lower total health care expenditures, 4% lower pharmacy expenditures, 15% lower rate of hospital inpatient visits, and 4% lower rate of medical provider visits. Both PCS/MCS are score 0-100 with 100 indicating the highest level of health. (NCT03540030)
Timeframe: 2 Months
Intervention | score on a scale (Median) | |
---|---|---|
PCS | MCS | |
Non-Opioid Intervention | 40.3 | 60.8 |
Observational | 38.4 | 58.7 |
quality of life using VR-12 subscores. Physical Health (PCS) subscore and Mental Health (MCS) subscore, not summed. Range reported in weighted units. Physical Health subscore: 1 point increase in PCS is associated with 6% lower total health care expenditures, 5% lower pharmacy expenditures, 9% lower rate of hospital inpatient visits, 4% lower rate of medical provider visits, 5% lower rate of hospital outpatient visits. Mental Health sub score a 1 point increase in MCS is associated with 7% lower total health care expenditures, 4% lower pharmacy expenditures, 15% lower rate of hospital inpatient visits, and 4% lower rate of medical provider visits. Both PCS/MCS are score 0-100 with 100 indicating the highest level of health. (NCT03540030)
Timeframe: 2 Weeks
Intervention | score on a scale (Median) | |
---|---|---|
PCS | MCS | |
Non-Opioid Intervention | 35.0 | 59.1 |
Observational | 36.7 | 56.3 |
The Roland-Morris Disability Questionnaire is designed to assess self-rated physical disability caused by low back pain. The patient is asked to agree or disagree with 24 different statements related to their back pain. The end score is the sum of the agreed statements. The score ranges from 0 (no disability) to 24 (maximum disability). (NCT02146482)
Timeframe: Baseline (Week 1) and Follow-Up (Week 18)
Intervention | units on a scale (Median) | |
---|---|---|
Baseline | Follow Up | |
Control | 6 | 4 |
Sit-stand Computer Workstation | 8.5 | 1.5 |
31 reviews available for acetaminophen and Chronic Pain
Article | Year |
---|---|
The Effects of Pain and Analgesic Medications on Blood Pressure.
Topics: Acetaminophen; Adrenergic Agents; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ster | 2022 |
Strategies of analgesic treatment after cesarean delivery. Current state and new alternatives.
Topics: Acetaminophen; Analgesia, Obstetrical; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthesia, Epi | 2020 |
Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Anticonvulsants; Antidepressiv | 2020 |
Paracetamol for low back pain: the state of the research field.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Low Back Pain; Randomized | 2020 |
The pharmacological management of chronic lower back pain.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; C | 2021 |
Paracetamol (acetaminophen) for chronic non-cancer pain in children and adolescents.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Chronic Pain; Humans | 2017 |
Impact of medication on protein and amino acid metabolism in the elderly: the sulfur amino acid and paracetamol case.
Topics: Acetaminophen; Aged; Amino Acids, Sulfur; Animals; Chronic Pain; Cysteine; Dietary Proteins; Frail E | 2018 |
Novel Pharmacological Nonopioid Therapies in Chronic Pain.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Chronic Pain; Humans; Opioid-R | 2018 |
Understanding osteoporotic pain and its pharmacological treatment.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservatio | 2018 |
Long-term adverse effects of paracetamol - a review.
Topics: Acetaminophen; Acute Kidney Injury; Analgesics, Non-Narcotic; Asthma; Cardiovascular Diseases; Chron | 2018 |
[Errors and Solutions During Medical Therapy for Chronic Pain].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 2018 |
Opioid Adjuncts: Optimizing Opioid Therapy With Nonopioid Medications.
Topics: Acetaminophen; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2019 |
Revisiting established medicines: An overview of systematic reviews about ibuprofen and paracetamol for treating pain in children.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, N | 2019 |
Evidence-Based Recommendations on the Pharmacological Management of Osteoarthritis and Chronic Low Back Pain: An Asian Consensus
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidep | 2019 |
Tramadol and acetaminophen combination for chronic non-cancer pain.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Chronic Pain; Drug Combination | 2013 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
Postoperative pain management after total knee arthroplasty in elderly patients: treatment options.
Topics: Acetaminophen; Acute Pain; Aged; Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anti-Inflam | 2014 |
An overview of pain management: the clinical efficacy and value of treatment.
Topics: Acetaminophen; Acute Disease; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chronic P | 2013 |
How to set boundaries with chronic pain patients.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Pain; Decision Support Techniqu | 2014 |
Understanding the cancer pain experience.
Topics: Acetaminophen; Analgesics; Chronic Pain; Critical Pathways; Fentanyl; Humans; Ketamine; Neoplasms; O | 2014 |
Management of opioid painkiller dependence in primary care: ongoing recovery with buprenorphine/naloxone.
Topics: Acetaminophen; Analgesics, Opioid; Buprenorphine; Chronic Pain; Codeine; Counseling; Fatigue Syndrom | 2014 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Humans; Ibuprofen | 2015 |
Pain management in the elderly.
Topics: Acetaminophen; Administration, Topical; Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Ant | 2015 |
Acetaminophen for Chronic Pain: A Systematic Review on Efficacy.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Chronic Disease; Chronic Pain; Databases, Factual; Humans; | 2016 |
Ongoing Pharmacological Management of Chronic Pain in Pregnancy.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chr | 2016 |
Advanced Concepts and Controversies in Emergency Department Pain Management.
Topics: Acetaminophen; Acute Pain; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agen | 2016 |
[Analgesic drugs during pregnancy].
Topics: Abnormalities, Drug-Induced; Acetaminophen; Acute Pain; Analgesics; Analgesics, Opioid; Anticonvulsa | 2016 |
Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Pain; Codeine; Humans; N | 2016 |
Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline.
Topics: Acetaminophen; Acute Pain; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Analgesics, Opioid; An | 2017 |
Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline.
Topics: Acetaminophen; Acute Pain; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Analgesics, Opioid; An | 2017 |
Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline.
Topics: Acetaminophen; Acute Pain; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Analgesics, Opioid; An | 2017 |
Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline.
Topics: Acetaminophen; Acute Pain; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Analgesics, Opioid; An | 2017 |
[Chronic pain following spine surgery].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 2012 |
[Skin ulcer pain].
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Chroni | 2012 |
Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chronic Pain | 2012 |
21 trials available for acetaminophen and Chronic Pain
Article | Year |
---|---|
Protocol for the RETHINK study: a randomised, double-blind, parallel-group, non-inferiority clinical trial comparing acetaminophen and NSAIDs for treatment of chronic pain in elderly patients with osteoarthritis of the hip and knee.
Topics: Acetaminophen; Activities of Daily Living; Aged; Analgesics; Anti-Inflammatory Agents, Non-Steroidal | 2023 |
Association of
Topics: Acetaminophen; Acute Pain; Breast Neoplasms; Chronic Pain; Female; Humans; MicroRNAs; Neuralgia; Rec | 2023 |
Evaluation of the Effect of New Multimodal Analgesia Regimen for Cardiac Surgery: A Prospective, Randomized Controlled, Single-Center Clinical Study.
Topics: Acetaminophen; Analgesia; Cardiac Surgical Procedures; Chronic Pain; Dexmedetomidine; Gabapentin; Hu | 2023 |
Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chronic Pain | 2020 |
A randomized-controlled pilot trial of an online compassionate mind training intervention to help people with chronic pain avoid analgesic misuse.
Topics: Acetaminophen; Adult; Analgesics; Analgesics, Opioid; Arthritis, Rheumatoid; Aspirin; Back Pain; Chr | 2020 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-In | 2018 |
Effect of effervescent paracetamol on blood pressure: a crossover randomized clinical trial.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Antihypertensive Agents; Blood Pressure; Blood Pressu | 2018 |
Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM).
Topics: Acetaminophen; Administration, Cutaneous; Aged, 80 and over; Analgesics; Buprenorphine; Chronic Pain | 2018 |
Acetaminophen reduces acute and persistent incisional pain after hysterectomy.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Chronic Pain; Female; Humans; Hysterectomy; Pai | 2018 |
A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain.
Topics: Acetaminophen; Adult; Aged; Analgesics; Chronic Pain; Delayed-Action Preparations; Double-Blind Meth | 2013 |
Do analgesics improve functioning in patients with chronic low back pain? An explorative triple-blinded RCT.
Topics: Acetaminophen; Adult; Analgesics; Chronic Pain; Disability Evaluation; Double-Blind Method; Drug Adm | 2014 |
Endogenous pain modulation in response to exercise in patients with rheumatoid arthritis, patients with chronic fatigue syndrome and comorbid fibromyalgia, and healthy controls: a double-blind randomized controlled trial.
Topics: Acetaminophen; Adult; Aged; Analgesia; Analgesics, Non-Narcotic; Arthritis, Rheumatoid; Chronic Pain | 2015 |
Intermittent epidural vs continuous wound infusion of ropivacaine for acute and chronic pain control after hysterectomy or myomectomy: a randomized controlled trial.
Topics: Acetaminophen; Acute Pain; Adult; Amides; Analgesia, Epidural; Analgesics; Anesthetics, Local; Chron | 2014 |
Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Pain; Double-Blind | 2015 |
Analgesia evaluation of 2 NSAID drugs as adjuvant in management of chronic temporomandibular disorders.
Topics: Acetaminophen; Adult; Aged; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Carisoprod | 2015 |
Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Pain; Delayed-Acti | 2015 |
Preoperative dexamethasone reduces acute but not sustained pain after lumbar disk surgery: a randomized, blinded, placebo-controlled trial.
Topics: Acetaminophen; Acute Pain; Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammato | 2015 |
Balneotherapy for chronic low back pain: a randomized, controlled study.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Analysis of Variance; Balneology; Chi-Square Distribu | 2012 |
[Ibuprofen/paracetamol combination therapy is more effective than monotherapy in knee pain, but increases bleeding risk].
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Chronic Pai | 2012 |
Effect of adding cervical facet joint injections in a multimodal treatment program for long-standing cervical myofascial pain syndrome with referral pain patterns of cervical facet joint syndrome.
Topics: Acetaminophen; Anesthetics, General; Chronic Pain; Clonidine; Codeine; Combined Modality Therapy; Do | 2012 |
Perioperative pregabalin for acute and chronic pain after abdominal hysterectomy or myomectomy: a randomised controlled trial.
Topics: Acetaminophen; Acute Pain; Adult; Analgesics; Chronic Pain; Codeine; Double-Blind Method; Drug Combi | 2012 |
40 other studies available for acetaminophen and Chronic Pain
Article | Year |
---|---|
Practice guidelines for the treatment of acute migraine and chronic knee osteoarthritis with paracetamol: an expert appraisal on evolution over time between scientific societies.
Topics: Acetaminophen; Chronic Pain; Humans; Migraine Disorders; Osteoarthritis, Hip; Osteoarthritis, Knee; | 2022 |
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report.
Topics: Acetaminophen; Analgesics, Opioid; Animals; Breakthrough Pain; Buprenorphine; Cattle; Chronic Pain; | 2023 |
Analgesic utilization in people with knee osteoarthritis: A population-based study using primary care data.
Topics: Acetaminophen; Adult; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chron | 2023 |
Perceptions of West Virginia Teens and Adults Regarding the Risks of Over-the-Counter Pain Medications.
Topics: Acetaminophen; Adolescent; Adult; Chronic Pain; Humans; Nonprescription Drugs; Surveys and Questionn | 2023 |
Presence and grade of undertreatment of pain in children with cerebral palsy.
Topics: Acetaminophen; Adaptation, Psychological; Adolescent; Adult; Cerebral Palsy; Child; Child, Preschool | 2023 |
A new OPIATE (Optimizing Positive Ibuprofen and Acetaminophen Treatment Expectations) model: A brief comment on "Concurrent and lagged associations of prescription opioid use with pain and negative affect in the daily lives of chronic pain patients" (Carp
Topics: Acetaminophen; Affect; Analgesics, Opioid; Chronic Pain; Humans; Ibuprofen; Motivation; Opiate Alkal | 2019 |
Efficacy and safety of modified-release paracetamol for acute and chronic pain: a systematic review protocol.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adult; Australia; Child; Child, Preschool; Chron | 2019 |
Attitudes toward and Barriers to Acetaminophen Use in the Chronic Pain Population: A Cross-Sectional Study.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Attitude; Chronic Pain; Cross-Sectional Studies; Fema | 2020 |
Physician-Delivered Pain Neuroscience Education for Opioid Tapering: A Case Report.
Topics: Acetaminophen; Aged; Analgesics, Opioid; Chronic Pain; Female; Fentanyl; Humans; Hydrocodone; Low Ba | 2020 |
Influence of acetaminophen on renal function: a longitudinal descriptive study using a real-world database.
Topics: Acetaminophen; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2021 |
A retrospective analysis of the effects of different analgesics on the pain of patients with traumatic thoracolumbar fractures in the peri-treatment period.
Topics: Acetaminophen; Acute Pain; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Chronic Pain; Cod | 2021 |
Oral Multimodal Analgesia for Total Joint Arthroplasty.
Topics: Acetaminophen; Analgesia; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Arthroplasty, Re | 2017 |
Ginger rhizome enhances the anti-inflammatory and anti-nociceptive effects of paracetamol in an experimental mouse model of fibromyalgia.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Chronic Pain; Disease Models, Animal; Drug Synergi | 2018 |
Opioids for Acute Pain: Proceed with Caution.
Topics: Acetaminophen; Acute Pain; Adult; Analgesics, Opioid; Chronic Pain; Drug Combinations; Female; Fract | 2018 |
[Side Effects of Acetaminophen and their Management].
Topics: Acetaminophen; Aspirin; Chronic Pain; Cyclooxygenase 1; Fever; Humans; Pain Management; Reye Syndrom | 2016 |
The glycation products before and after therapy for acute and chronic pain.
Topics: Acetaminophen; Acute Pain; Adult; Analgesics, Opioid; Biomarkers; Chronic Pain; Female; Glycation En | 2018 |
Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Carbamazepine; Chronic Pain | 2019 |
Ethical quandaries in caring for primary-care patients with chronic pain.
Topics: Acetaminophen; Back Pain; Behavioral Medicine; Chronic Pain; Clinical Competence; Codes of Ethics; D | 2013 |
The management of HIV- and AIDS-related pain in a primary health clinic in Tshwane, South Africa.
Topics: Acetaminophen; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Analgesics, Non-Narcotic | 2013 |
[Tramadol/acetaminophen combination tablets].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic Pain; Drug Combinations; Humans | 2013 |
Rational prescribing.
Topics: Acetaminophen; Analgesics, Opioid; Chronic Pain; Drug Combinations; Humans; Long-Term Care; Minnesot | 2013 |
The therapeutic management of chronic pain in ambulatory care patients aged 65 and over in France: the S.AGES Cohort. Baseline data.
Topics: Acetaminophen; Aged; Aged, 80 and over; Ambulatory Care; Analgesics; Back Pain; Chronic Pain; Dextro | 2013 |
[Self-medication to treat pain in attacks of familial Mediterranean fever: aiming to find a new approach to pain management].
Topics: Acetaminophen; Adult; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chron | 2013 |
How safe is acetaminophen in rheumatology?
Topics: Acetaminophen; Cardiovascular Diseases; Chronic Pain; Humans; Musculoskeletal Pain; Osteoarthritis; | 2014 |
Pregabalin reduces opioid consumption and improves outcome in chronic pain patients undergoing total knee arthroplasty.
Topics: Acetaminophen; Aged; Analgesics; Analgesics, Opioid; Arthroplasty, Replacement, Knee; Celecoxib; Chr | 2014 |
Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Blood Pressure; Chronic Pain; Confounding Factors, Ep | 2015 |
Should acetaminophen be added to the list of anti-inflammatory agents that are associated with cardiovascular events?
Topics: Acetaminophen; Blood Pressure; Chronic Pain; Female; Humans; Hypertension; Male; Myocardial Infarcti | 2015 |
Sucrose-induced analgesia during early life modulates adulthood learning and memory formation.
Topics: Acetaminophen; Analgesics; Animals; Animals, Newborn; beta-Endorphin; Chronic Pain; Disease Models, | 2015 |
Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription of opioids.
Topics: Acetaminophen; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Aspirin; | 2015 |
Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
Topics: Acetaminophen; Acute Pain; Administration, Intranasal; Analgesics, Opioid; Chronic Pain; Delayed-Act | 2016 |
The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Austral | 2015 |
Overall safety profile and effectiveness of tramadol hydrochloride/acetaminophen in patients with chronic noncancer pain in Japanese real-world practice.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Chronic | 2015 |
Effect of Preoperative Inflammatory Status and Comorbidities on Pain Resolution and Persistent Postsurgical Pain after Inguinal Hernia Repair.
Topics: Acetaminophen; Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chronic Pai | 2016 |
Chronic pain among community-dwelling elderly: a population-based clinical study.
Topics: Acetaminophen; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Ster | 2016 |
Analgesic drugs and the gut - a reciprocal relationship.
Topics: Acetaminophen; Administration, Oral; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agent | 2015 |
A case of delayed onset pyroglutamic acidosis in the sub-acute setting.
Topics: Acetaminophen; Acidosis, Renal Tubular; Aged; Chronic Pain; Floxacillin; Humans; Male; Osteomyelitis | 2016 |
Effect of Tramadol/Acetaminophen on Motivation in Patients with Chronic Low Back Pain.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Apathy; | 2016 |
Pain severity and pharmacologic pain management among community-living older adults: the MOBILIZE Boston study.
Topics: Acetaminophen; Aged; Aged, 80 and over; Analgesics; Analgesics, Opioid; Chronic Pain; Cohort Studies | 2017 |
Surrogate decision making: a woman in fulminant liver failure after an acetaminophen overdose.
Topics: Acetaminophen; Advance Care Planning; Analgesics, Non-Narcotic; Chronic Pain; Critical Care; Decisio | 2011 |
Analgesic use in a national community sample of German children and adolescents.
Topics: Acetaminophen; Acute Pain; Adolescent; Analgesics; Aspirin; Child; Child, Preschool; Chronic Pain; F | 2012 |